bioRxiv · 10.1101/2022.10.29.514376
Improving the sensitivity of in vivo CRISPR off-target detection with DISCOVER-Seq+
Abstract
Discovery of off-target CRISPR-Cas genome editing activity in patient-derived cells and animal models is crucial for therapeutic applications, but currently exhibits low sensitivity. We demonstrate that inhibition of DNA-dependent protein kinase catalytic subunit (DNA-PKcs) accumulates repair protein MRE11 at CRISPR-targeted sites, enabling high-sensitivity mapping of off-target sites to positions of MRE11 binding using chromatin immunoprecipitation sequencing (ChIP-seq). This technique, termed DISCOVER-Seq+, discovered up to 5-fold more CRISPR off-target sites in immortalized cell lines, primary human cells, and mice compared to previous methods. We demonstrated applicability to ex vivo knock-in of a cancer-directed transgenic T-cell receptor in primary human T cells and in vivo adenovirus knock-out of cardiovascular risk gene PCSK9 in mice. DISCOVER-Seq+ is the most sensitive method to-date for discovering off-target genome editing in vivo.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Zou, R. S., Liu, Y., Reyes Gaido, O. E., Konig, M. F., Mog, B. J., Shen, L. L., Aviles-Vazquez, F., Marin-Gonzalez, A., Ha, T.. 2022-10-30. Improving the sensitivity of in vivo CRISPR off-target detection with DISCOVER-Seq+. https://doi.org/10.1101/2022.10.29.514376
Cite the original work for its findings. Save a collection to share your selection of sources.